CHMP provides conditional reprieve for Fampyra
This article was originally published in Scrip
After having first declined an opportunity to recommend Fampyra (fampridine) from Biogen Idec and Acorda Therapeutics, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the granting of market authorisation for use in improving the walking ability of adults with multiple sclerosis at its 16-19 May meeting. In January, the CHMP gave a negative opinion but at the request of Biogen Idec the committee re-examined its position.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.